Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/21856
Title: Tocilizumab Labeling with (99m)Technetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma
Authors: CAMACHO, XimenaMACHADO, Camila LongoGARCIA, Maria FernandaFERNANDEZ, MarceloODDONE, NataliaBENECH, JuanGAMBINI, Juan PabloCERECETTO, HugoCHAMMAS, RogerCABRALA, PabloRIVA, Eloisa
Citation: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v.17, n.9, p.1267-1277, 2017
Abstract: Background: Multiple myeloma is the second most common hematological malignancy. Interleukin-6 (IL-6) is one of the key molecules related to growth, survival and proliferation of myeloma cells. Tocilizumab is a humanized monoclonal antibody directed against receptor of IL-6. Objective: To radiolabel Tocilizumab with (99m)Technetium as a potential imaging agents for MM. Methods: IL-6R expression was studied by laser confocal microscopy in MM cell lines (U266, NCI-H929 and MM1S). Tocilizumab was derivatized with NHS-HYNIC-Tfa and radiolabeling with Tc-99m. Radiochemical stability was determined. In-vitro binding and immunoreactive fraction assays were performed. Biodistribution and SPECT/CT imaging were evaluated in healthy BALB/c and MM-bearing BALB/c nude mice. Results: LCM studies allowed us to demonstrate that U266, NCI-H929 and MM1S cells present high expression of IL-6R in cell membrane. Radiolabeling was carried out in a fast, reproducible, easy and stable way having high radiochemical purity and did not interfere with epitope recognition. The immunoreactive fraction of (TcHYNIC)-Tc-99m-Tocilizumab was 86.35%. Biodistribution showed a high uptake in liver, spleen, gastrointestinal tract and kidneys. SPECT/CT imaging of MM-bearing BALB/c nude mice showed liver uptake and a high tumor selective uptake at 24 hours. Conclusions: Our results support the potential role of 99mTc-HYNIC-Tocilizumb as a novel MM radiotracer for targeting IL-6 expression in-vivo. We describe the development of a formulation kit to radiolabeling monoclonal antibodies in a clinical setting. We hope that these novel molecular imaging agents will open the path to new diagnostic and therapeutic strategies for MM disease.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - LIM/24
LIM/24 - Laboratório de Oncologia Experimental

Artigos e Materiais de Revistas Científicas - LIM/43
LIM/43 - Laboratório de Medicina Nuclear

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_CAMACHO_Tocilizumab_Labeling_with_99mTechnetium_via_HYNIC_as_a_2017.PDF
  Restricted Access
publishedVersion (English)4.65 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.